Treatment of children and adolescents with idiopathic short stature

Nature Reviews Endocrinology

Volumn 9, Issue 6, 2013, Pages 325-334

  Ranke, Michael B ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; GONADORELIN AGONIST; GROWTH HORMONE; LETROZOLE; OXANDROLONE; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TESTOSTERONE ESTER;

ADOLESCENT DISEASE; BODY HEIGHT; CHILD GROWTH; CHILDHOOD DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; GROWTH HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; IDIOPATHIC DISEASE; IDIOPATHIC SHORT STATURE; PRIORITY JOURNAL; PUBERTY; REVIEW; SHORT STATURE;

DWARFISM, PITUITARY; HUMAN GROWTH HORMONE; HUMANS;

EID: 84879107445     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2013.71     Document Type: Review

References (141)

1. Wit, J. M. et al. Idiopathic short stature: definition, epidemiology, and diagnostic evaluation. Growth Horm. IGF Res. 18, 89-110 (2008).
2. Wit, J. M. et al. Idiopathic short stature: management and growth hormone treatment. Growth Horm. IGF Res. 18, 111-35 (2008).
3. Cohen, P. et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J. Clin. Endocrinol. Metab. 93, 4210-4217 (2008).
4. Wit, J. M. Developments in idiopathic short stature (ed. Dunkel, L.). Horm. Res. Pediatr. 76 (Suppl. 3), 1-60 (2011)
5. Ranke, M. B. Towards a consensus on the definition of idiopathic short stature. Horm. Res. 45 (Suppl. 2), 64-66 (1996).
6. Hermanussen, M. & Cole, J. The calculation of target height reconsidered. Horm. Res. 59, 180-183 (2003).
7. Delemarre-van de Waal, H. A. Secular trend of timing of puberty. Endocr. Dev. 8, 1-14 (2005).
8. Weedon, M. N. et al. Genome-wide association analysis identifies 20 loci that influence adult height. Nat. Genet. 40, 575-583 (2008).
9. Lettre, G. Genetic regulation of adult stature. Curr. Opin. Pediatr. 21, 515-522 (2009).
10. Lui, J. C. et al. Synthesizing genome-wide association studies and expression microarray reveals novel genes that act in the human growth plate to modulate height. Hum. Mol. Genet. 21, 5193-5201 (2012).
11. Chan, Y. et al. Common variants show predicted polygenic effects on height in the tails of the distribution, except in extremely short individuals. PLoS Genet. 7, e1002439 (2011).
12. Ojeda, S. R. et al. The transcriptional control of female puberty. Brain Res. 1364, 164-174 (2010).
13. Roa, J., García-Galiano, D., Castellano, J. M., Gaytan, F., Pinilla, L. & Tena-Sempere, M. Metabolic control of puberty onset: new players, new mechanisms. Mol. Cell Endocrinol. 324, 87-94 (2010).
14. Gajdos, Z. K., Henderson, K. D., Hirschhorn, J. N. & Palmert, M. R. Genetic determinants of pubertal timing in the general population. Mol. Cell Endocrinol. 324, 21-29 (2010).
15. Elks, C. E. et al. Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat. Genet. 42, 1077-1085 (2010).
16. Elks, C. E. & Ong, K. K. Whole genome associated studies for age at menarche. Brief. Funct. Genomics 10, 91-97 (2011).
17. Cole, T. J. Secular trends in growth. Proc. Nutr. Soc. 59, 317-324 (2000).
18. Delemarre-van de Waal, H. A. Secular trend of timing of puberty. Endocr. Dev. 8, 1-14 (2005).
19. Bourguignon, J. P. & Juul, A. Normal female puberty in a developmental perspective. Endocr. Dev. 22, 11-23 (2012).
20. Tinggaard, J. et al. The physiology and timing of male puberty. Curr. Opin. Endocrinol. Diabetes Obes. 19, 197-203 (2012).
21. Ong, K. K., Ahmed, M. L. & Dunger, D. B. Lessons from large population studies on timing and tempo of puberty (secular trends and relation to body size): the European trend. Mol. Cell Endocrinol. 254-255, 8-12 (2006).
22. World Health Organization. The WHO child growth standards. World Health Organization [online], http://www.who.int/childgrowth/standards/height-for-age/ en/index.html (2008).
23. Johnston Rohrbasser, L. B. Genetic testing in short children. Horm. Res. Pediatr. 76 (Suppl. 3), 13-16 (2011).
24. Ranke, M. B. et al. Significance of basal IGF-1, IGFBP-3 and IGFBP-2 measurements in the diagnostics of short stature children. Horm. Res. 54, 60-68 (2000).
25. Walenkamp, M. J. & Wit, J. M. Genetic disorders in the growth hormone insulin-like growth factor-I axis. Horm. Res. 66, 221-230 (2006).
26. Clemmons, D. R. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin. Chem. 57, 555-559 (2011).
27. Ranke, M. B. in Diagnostics of Endocrine Function in Children and Adolescents 4th edn (eds Ranke, M. B. & Mullis, P. E.), 102-137 (Karger, Basel, 2011).
28. Binder, G. Growth hormone deficiency: new approaches to the diagnosis. Pediatr. Endocrinol. Rev. 9 (Suppl. 1), 535-537 (2011).
29. David, A. et al. Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity. Endocr. Rev. 32, 472-497 (2011).
30. Forbes, B. E. Molecular mechanisms underlying insulin-like growth factor action: How mutations in the GH: IGF axis lead to short stature. Pediatr. Endocrinol. Rev. 8, 374-381 (2011).
31. Rappold, G. et al. Genotypes and phenotypes in children with short stature: clinical indicators of SHOX haploinsufficiency. J. Med. Genet. 44, 306-313 (2007).
32. Caliebe, J. et al. IGF1R and SHOX mutation analysis in short children born small for gestational age and short children with normal birth size (idiopathic short stature). Horm. Res. Paediatr. 77, 250-260 (2012).
33. Pugliese-Pires, P. N. et al. Novel inactivating mutations in the GH secretagogue receptor gene in patients with constitutional delay of growth and puberty. Eur. J. Endocrinol. 165, 233-241 (2011).
34. Inoue, H. et al. Identification and functional analysis of novel human growth hormone secretagogue receptor (GHSR) gene mutations in Japanese subjects with short stature. J. Clin. Endocrinol. Metab. 96, E373-E378 (2011).
35. Olney, R. C. et al. Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. J. Clin. Endocrinol. Metab. 91, 1229-1232 (2006).
36. Xiao, Y. et al. Measurement of amino-terminal propeptide of C-type natriuretic peptide in patients with idiopathic short stature or isolated growth hormone deficiency. J. Pediatr. Endocrinol. Metab. 24, 989-994 (2011).
37. Price, D. A. Spontaneous adult height in patients with idiopathic short stature. Horm. Res. 45 (Suppl. 2), 59-63 (1996).
38. Ranke, M. B., Grauer, M. L., Kistner, K., Blum, W. F. & Wollmann, H. A. Spontaneous adult height in idiopathic short stature. Horm. Res. 44, 152-157 (1995).
39. Rekers-Mombarg, L. T. et al. Spontaneous growth in idiopathic short stature. European Study Group. Arch. Dis. Child. 75, 175-180 (1996).
40. Martin, D. D. et al. The use of bone age in clinical practice-part 1. Horm. Res. Paediatr. 76, 1-9 (2011).
41. Topor, L. S., Feldman, H. A., Bauchner, H. & Cohen L. E. Variation in methods of predicting adult height for children with idiopathic short stature. Pediatrics 126, 938-944 (2010).
42. Thodberg, H. H., Jenni, O. G., Caflisch, J., Ranke, M. B. & Martin, D. D. Prediction of adult height based on automated determination of bone age. J. Clin. Endocrinol. Metab. 94, 4868-4874 (2009).
43. Noeker, M. & Haverkamp, F. Adjustment in conditions with short stature: a conceptual framework. J. Pediatr. Endocrinol. Metab. 13, 1585-1594 (2009).
44. Bullinger, M. Psychological criteria for treating children with idiopathic short stature. Horm. Res. Paediatr. 76 (Suppl. 3), 20-23 (2011).
45. Mobbs, E. J. The psychological outcome of constitutional delay of growth and puberty. Horm. Res. 62 (Suppl. 1), 1-66 (2005).
46. Kranzler, J. H., Rosenbloom, A. L., Proctor, B., Diamond, F. B. Jr & Watson, M. Is short stature a handicap? A comparison of the psychosocial functioning of referred and nonreferred children with normal short stature and children with normal stature. J. Pediatr. 136, 96-102 (2000).
47. Voss, L. D. Short normal stature and psychosocial disadvantage: a critical review of the evidence. J. Pediatr. Endocrinol. Metab. 14, 701-711 (2001).
48. Visser-van Balen, H., Sinnema, G. & Geenen, R. Growing up with idiopathic short stature: psychosocial development and hormone treatment; a critical review. Arch. Dis. Child. 91, 433-439 (2006).
49. Sandberg, D. E. & Colsman, M. Growth hormone treatment of short stature: Status of quality of life rationale. Horm. Res. 63, 275-283 (2005).
50. Christensen, T. L., Djurhuus, C. B., Clayton, P. & Christiansen, J. S. An evaluation of the relationship between adult height and health-related quality of life in the general UK population. Clin. Endocrinol. (Oxf.) 67, 407-412 (2007).
51. Allen, D. B. Clinical review: Lessons learned from the hGH era. J. Clin. Endocrinol. Metab. 96, 3042-3047 (2011).
52. LeRoith, D. Clinical relevance of systemic and local IGF-I: lessons from animal models. Pediatr. Endocrinol. Rev. 5 (Suppl. 2), 739-743 (2008).
53. Wit, J. M. & Camacho-Hübner, C. Endocrine regulation of longitudinal bone growth. Endocr. Dev. 21, 30-41 (2011).
54. Lui, J. C., Nilsson, O. & Baron, J. Growth plate senescence and catch-up growth. Endocr. Dev. 21, 23-29 (2011).
55. Lui, J. C. & Baron, J. Mechanisms limiting body growth in mammals. Endocr. Rev. 32, 422-440 (2011).
56. Emons, J., Chagin, A. S., Sävendahl, L., Karperien, M. & Wit, J. M. Mechanisms of growth plate maturation and epiphyseal fusion. Horm. Res. Paediatr. 75, 383-391 (2011).
57. Ren, S. G. et al. Direct administration of testosterone increases rat tibial epiphyseal growth plate width. Acta Endocrinol. (Copenh.) 121, 401-405 (1989).
58. Giustina, A. & Veldhuis, J. D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr. Rev. 19, 717-797 (1998).
59. De Luca, F. et al. Management of puberty in constitutional delay of growth and puberty. J. Pediatr. Endocrinol. Metab. 14 (Suppl. 2), 953-957 (2001).
60. Ambler, G. R. Androgen therapy for delayed male puberty. Curr. Opin. Endocrinol. Diabetes Obes. 16, 232-239 (2009).
61. Kiess, W. et al. Induction of puberty in the hypogonadal girl-practices and attitudes of pediatric endocrinologists in Europe. Horm. Res. 57, 66-71 (2002).
62. Drobac, S., Rubin, K., Rogol, A. D. & Rosenfield, R. L. A workshop on pubertal hormone replacement options in the United States. J. Pediatr. Endocrinol. Metab. 19, 55-64 (2006).
63. Kelly, B. P., Paterson W. F. & Donaldson, M. D. Final height outcome and value of height prediction in boys with constitutional delay in growth and adolescence treated with intramuscular testosterone 125 mg per month for 3 months, Clin. Endocrinol. (Oxf.) 58, 267-272 (2003).
64. Martin, M. M., Martin, A. L. & Mossman, K. L. Testosterone treatment of constitutional delay in growth and development: effect of dose on predicted versus definitive height. Acta Endocrinol. Suppl. (Copenh.) 279, 147-152 (1986).
65. Zachmann, M., Studer, S. & Prader, A. Short-term testosterone treatment at bone age of 12 to 13 years does not reduce adult height in boys with constitutional delay of growth and adolescence. Helv. Paediatr. Acta. 42, 21-28 (1987).
66. Arrigo, T. et al. Final height outcome in both untreated and testosterone-treated boys with constitutional delay of growth and puberty. J. Pediatr. Endocrinol. Metab. 9, 511-517 (1996).
67. Wehkalampi, K., Päkkilä, K., Laine, T. & Dunkel, L. Adult height girls with delayed pubertal growth. Horm. Res. Paediatr. 76, 130-135 (2011).
68. Stanhope, R., Buchanan, C. R., Fenn., G. C. & Preece, M. A. Double blind placebo controlled trial of low dose oxandrolone in the treatment of boys with constitutional delay of growth and puberty. Arch. Dis. Child. 63, 501-505 (1988).
69. Wilson, D. M., McCauley, E., Brown, D. R. & Dudley, R. Oxandrolone therapy in constitutionally delayed growth and puberty. Bio-Technology General Corporation Cooperative Study Group. Pediatrics 96, 1095-1100 (1995).
70. Tse, W. Y. et al. Long-term outcome of oxandrolone treatment in boys with constitutional delay of growth and puberty. J. Pediatr. 117, 588-591 (1990).
71. Menke, L. A. et al. Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome. J. Clin. Endocrinol. Metab. 95, 1151-1160 (2010).
72. Carel, J. C. et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 123, e752-e762 (2009).
73. Yanovski, J. A. et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N. Engl. J. Med. 348, 908-917 (2003).
74. Wit, J. M., Balen, H. V., Kamp, G. A. & Oostdijk, W. Benefit of postponing normal puberty for improving final height. Eur. J. Endocrinol. 151 (Suppl. 1), 41-45 (2004).
75. Reiter, E. O. A brief review of the addition of gonadotropin-releasing hormone agonists (GnRH-Ag) to growth hormone (GH) treatment of children with idiopathic growth hormone deficiency: Previously published studies from America. Mol. Cell Endocrinol. 254-255, 221-225 (2006).
76. Mauras, N. Strategies for maximizing growth in puberty in children with short stature. Pediatr. Clin. North Am. 58, 1167-1179 (2011).
77. Tanaka, T. et al. GH and GnRH analog treatment in children who enter puberty at short stature. J. Pediatr. Endocrinol. Metab. 10, 623-628 (1997).
78. van Gool, S. A. et al. Final outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty. J. Clin. Endocrinol. Metab. 92, 1402-1408 (2007).
79. Smith, E. P. et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331, 1056-1061 (1994).
80. Morishima, A. Grumbach, M. M., Simpson, E. R. Fisher, C. & Qin, K. Aromatase deficiency in male and female sibling caused by a novel mutation and the physiological role of estrogens. J. Clin. Endocrinol. Metab. 80, 3689-3698 (1995).
81. Rochira, V. et al. Tall stature without growth hormone: four male patients with aromatase deficiency. J. Clin. Endocrinol. Metab. 95, 1626-1633 (2010).
82. Wickman, S., Sipilä, I., Ankarberg-Lindgren, C., Norjavaara, E. & Dunkel, L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 357, 1743-1748 (2001).
83. Salehpour, S. et al. A double-blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature. Horm. Res. Paediatr. 74, 428-435 (2010).
84. Hero, M., Wickman, S. & Dunkel, L. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin. Endocrinol. (Oxf.) 64, 510-513 (2006).
85. Dunkel, L. Treatment of idiopathic short stature: effects of gonadotropin-releasing hormone analogs, aromatase inhibitors and anabolic steroids. Horm. Res. Paediatr. 76 (Suppl. 3), 27-29 (2011).
86. Hopwood, N. J. et al. Growth response of children with non-growth-hormone deficiency and marked short stature during three years of growth hormone therapy. J. Pediatr. 123, 215-222 (1993).
87. Loche, S. et al. Final height after growth hormone therapy in non-growth-hormone-deficient children with short stature. J. Pediatr. 125, 196-200 (1994).
88. Barton, J. S. et al. The growth and cardiovascular effects of high dose growth hormone therapy in idiopathic short stature. Clin. Endocrinol. (Oxf.) 42, 619-626 (1995).
89. Lanes, R. Effects of two years of growth hormone treatment in short, slowly growing non-growth hormone deficient children. J. Pediatr. Endocrinol. Metab. 8, 167-171 (1995).
90. Wit, J. M., Kamp, G. A. & Rikken, B. Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature. Pediatr. Res. 39, 295-302 (1996).
91. Hindmarsh, P. C. & Brook, C. G. Final height of short normal children treated with growth hormone. Lancet 348, 13-16 (1996).
92. Bernasconi, S., Street, M. E., Volta, C. & Mazzardo, G. Final height in non-growth hormone deficient children treated with growth hormone. The Italian Multicentre Study Group. Clin. Endocrinol. (Oxf.) 47, 261-266 (1997).
93. Kawai, M. et al. Unfavorable effects of growth hormone therapy on the final height of boys with short stature not caused by growth hormone deficiency. J. Pediatr. 130, 205-209 (1997).
94. Zadik, Z. & Zung, A. Final height after growth hormone therapy in short children: correlation with siblings' height. Horm. Res. 48, 274-277 (1997).
95. Buchlis, J. G. et al. Comparison of final heights of growth hormone-treated vs. untreated children with idiopathic growth failure. J. Clin. Endocrinol. Metab. 83, 1075-1079 (1998).
96. McCaughey, E. S., Mulligan, J., Voss, L. D. & Betts, P. R. Randomised trial of growth hormone in short normal girls. Lancet 351, 940-944 (1998).
97. Hintz, R. L., Attie, K. M., Baptista, J. & Roche, A. Effect of growth hormone treatment on adult height of children with idiopathic short stature. Genentech Collaborative Group. N. Engl. J. Med. 340, 502-507 (1999).
98. López-Siguero, J. P., Garciá-Garcia, E., Carralero, I. & Martínez-Aedo, M. J. Adult height in children with idiopathic short stature treated with growth hormone. J. Pediatr. Endocrinol. Metab. 13, 1595-1602 (2000).
99. Coutant, R. et al. Growth and adult height in GH-treated children with nonacquired GH deficiency and idiopathic short stature: the influence of pituitary magnetic resonance imaging findings. J. Clin. Endocrinol. Metab. 86, 4649-4654 (2001).
100. Wit, J. M. & Rekers-Mombarg, L. T. Final height gain by GH therapy in children with idiopathic short stature is dose dependent. J. Clin. Endocrinol. Metab. 87, 604-611 (2002).
101. Leschek, E. W. et al. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89, 3140-3148 (2004).
102. Kemp, S. F. et al. Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J. Clin. Endocrinol. Metab. 90, 5247-5253 (2005).
103. Wit, J. M. et al. Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect. J. Pediatr. 146, 45-53 (2005).
104. Albertsson-Wikland, K. et al. Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J. Clin. Endocrinol. Metab. 93, 4342-4350 (2008).
105. Lee, P. A. et al. Comparison of response to 2-years' growth hormone treatment in children with isolated growth hormone deficiency, born small for gestational age, idiopathic short stature, or multiple pituitary hormone deficiency: combined results from two large observational studies. Int. J. Pediatr. Endocrinol. 2012, 22 (2012).
106. Hughes, I. P. et al. Growth hormone regimens in Australia: analysis of the first 3 years of treatment for idiopathic growth hormone deficiency and idiopathic short stature. Clin. Endocrinol. (Oxf.). 77, 62-71 (2012).
107. Finkelstein, B. S. et al. Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis. Arch. Pediatr. Adolesc. Med. 156, 230-240 (2002).
108. Bryant, J., Baxter, L., Cave, C. B. & Milne, R. Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD004440. http://dx.doi.org/10.1002/14651858.CD004440.pub2
109. Hardin, D. S., Woo, J., Butsch, R. & Huett, B. Current prescribing practices and opinions about growth hormone therapy: results of a nationwide survey of paediatric endocrinologists. Clin. Endocrinol. (Oxf.). 66, 85-94 (2007).
110. Bang, P. et al. A comparison of different definitions of growth response in short prepubertal children treated with growth hormone. Horm. Res. Paediatr. 75, 335-345 (2011).
111. Bakker, B., Frane, J., Anhalt, H., Lippe, B. & Rosenfeld, R. G. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J. Clin. Endocrinol. Metab. 93, 352-357 (2008).
112. Ranke, M. B., Lindberg, A. & KIGS International Board. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J. Clin. Endocrinol. Metab. 95, 1229-1237 (2010).
113. Ranke, M. B. & Lindberg, A. Growth hormone treatment of idiopathic short stature: analysis of the database from KIGS, the Kabi Pharmacia International Growth Study. Acta Paediatr. Suppl. 406, 18-23 (1994).
114. Ranke, M. B. & Lindberg, A. Predicting growth in response to growth hormone treatment. Growth Horm. IGF Res. 19, 1-11 (2009).
115. Kamp, G. A. et al. Biochemical markers of growth hormone (GH) sensitivity in children with idiopathic short stature: individual capacity of IGF-I generation after high-dose GH treatment determines the growth response to GH. Clin. Endocrinol. (Oxf.). 57, 315-325 (2002).
116. Ranke, M. B. et al. Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. Horm. Res. 68, 53-62 (2007).
117. Ranke, M. B. & Lindberg, A. Observed and predicted total pubertal growth during treatment with growth hormone in adolescents with idiopathic growth hormone deficiency, Turner syndrome, short stature, born small for gestational age and idiopathic short stature: KIGS analysis and review. Horm. Res. Paediatr. 75, 423-432 (2011).
118. van Gool, S. A. et al. High-dose GH treatment limited to the prepubertal period in young children with idiopathic short stature does not increase adult height. Eur. J. Endocrinol. 162, 653-660 (2010).
119. Dahlgren, J. Metabolic benefits of growth hormone therapy in idiopathic short stature. Horm. Res. Paediatr. 76 (Suppl. 3), 56-58 (2011).
120. Stabler, B. et al. Behavior change after growth hormone treatment of children with short stature. J. Pediatr. 133, 366-373 (1998).
121. Chaplin, J. E. et al. Improvements in behaviour and self-esteem following growth hormone treatment in short prepubertal children. Horm. Res. Paediatr. 75, 291-303 (2011).
122. Theunissen, N. C. et al. Quality of life and self-esteem in children treated for idiopathic short stature. J. Pediatr. 140, 507-515 (2002).
123. Ross, J. L. et al. Psychological adaptation in children with idiopathic short stature treated with growth hormone or placebo. J. Clin. Endocrinol. Metab. 89, 4873-4878 (2004).
124. Allen, D. B. Safety of growth hormone treatment of children with idiopathic short stature: the US experience. Horm. Res. Paediatr. 76 (Suppl. 3), 45-47 (2011).
125. Cook, D. M. & Rose, S. R. A review of guidelines for use of growth hormone in pediatric and transition patients. Pituitary 15, 301-310 (2012).
126. Ross, J. et al. Growth hormone: health considerations beyond height gain. Pediatrics 125, e906-e918 (2010).
127. Bell, J. et al. Long-term safety of recombinant human growth hormone in children. J. Clin. Endocrinol. Metab. 95, 167-177 (2010).
128. Quigley, C. A. et al. Safety of growth hormone treatment in pediatric patients with idiopathic short stature. J. Clin. Endocrinol. Metab. 90, 5188-5196 (2005).
129. Wilton, P., Mattsson, A. F. & Darendeliler, F. Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). J. Pediatr. 157, 265-270 (2010).
130. Child, C. J. et al. Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research program. J. Clin. Endocrinol. Metab. 96, E1025-E1034 (2011).
131. Cutfield, W. S. et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 355, 610-613 (2000).
132. Hokken-Koelega, A. C., De Waal, W. J., Sas, T. C., Van Pareren, Y. & Arends, N. J. Small for gestational age (SGA): endocrine and metabolic consequences and effects of growth hormone treatment. J. Pediatr. Endocrinol. Metab. 17 (Suppl. 3), 463-469 (2004).
133. Carel, J. C. et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J. Clin. Endocrinol. Metab. 97, 416-425 (2012).
134. Sävendahl, L. et al. Long-term mortality and causes of death in isolated, GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J. Clin. Endocrinol. Metab. 97, E213-E217 (2012).
135. Rosenfeld, R. G. et al. Long-term surveillance of growth hormone therapy. J. Clin. Endocrinol. Metab. 97, 68-72 (2012).
136. Rosenfeld, R. G. The IGF system: new developments relevant to pediatric practice. Endocr. Dev. 9, 1-10 (2005).
137. Ranke, M. B. et al. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm. Res. 51, 128-134 (1999).
138. Chernausek, S. D. et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J. Clin. Endocrinol. Metab. 92, 902-910 (2007).
139. Savage, M. O. et al. Idiopathic short stature: will genetics influence the choice between GH and IGF-I therapy? Eur. J. Endocrinol. 157 (Suppl. 1), 33-37 (2007).
140. Midyett, L. K. et al. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. 95, 611-619 (2010).
141. Rosenbloom, A. L. Is there a role for recombinant insulin-like growth factor-I in the treatment of idiopathic short stature? Lancet 368, 612-616 (2006).